Core Viewpoint - The market price of 7-ACA is influenced by various factors, including changes in upstream chemical prices, industry supply and demand dynamics, production costs, and downstream market demand [1] Group 1: Company Insights - The company will closely monitor the trends in upstream raw material prices and overall market changes [1] - The company aims to develop a pricing strategy that considers its production and operational conditions, cost control capabilities, and competitive landscape [1] - The company emphasizes the importance of ensuring the rationality and competitiveness of its pricing strategy [1] Group 2: Industry Dynamics - The pricing of 7-ACA is affected by a combination of upstream chemical prices, supply-demand balance, production costs, and market demand [1] - The company acknowledges the need to consider multiple dynamic factors in the industry when setting prices [1]

Core Viewpoint - The company has fully integrated AI technology into its research, production, and commercialization processes, achieving tangible results through collaborations and innovations [2] Group 1: AI Integration and Achievements - The company has developed a biosynthetic gene cluster prediction algorithm architecture in collaboration with Tencent Quantum Laboratory, resulting in a published paper and a joint application for a national invention patent [2] - The DeepSeek model has been localized and deployed in the research phase, enhancing target identification, molecular design, and clinical trial efficiency [2] - AI is utilized in the production phase to optimize processes, predict capacity, and allocate resources effectively [2] Group 2: Commercialization and Future Plans - An AI agent has provided services to nearly 100,000 patients with chronic diseases, demonstrating the practical application of AI in healthcare [2] - The company plans to continue exploring deep applications of AI in the pharmaceutical and medical fields to drive further technological advancements [2]

Core Viewpoint - The company is actively advancing its financial digitalization system in alignment with industry characteristics and overall group development plans [2] Group 1: Financial Digitalization Efforts - The company is steadily promoting the establishment of a financial digitalization system [2] - It is exploring the feasibility of implementing a financial sharing model [2] - The company is continuously introducing various automation and intelligent digital tools to enhance financial processing efficiency and data management capabilities [2] Group 2: Future Plans - The financial digitalization construction will continue to evolve and improve alongside business development [2] - The company will persist in deepening its financial digitalization and intelligent transformation efforts [2] - Digital capabilities will be leveraged to empower business operations and development [2]

Core Viewpoint - Health元 (600380) reported that as of September 30, 2025, the number of shareholders reached 81,433 [1] Summary by Category - **Company Information** - Health元 has 81,433 shareholders as of the end of Q3 2025 [1]

Core Viewpoint - The company is actively monitoring developments and collaboration opportunities in the AI pharmaceutical sector, aiming to integrate AI technology with innovative drug research and development across the entire industry chain [1] Group 1 - The company is exploring multidimensional AI innovative drug research and development collaborations with quality partners in the industry [1] - The company will evaluate and actively promote any strategic collaboration opportunities that align with its development goals [1] - The company commits to timely information disclosure if there are any substantial advancements in related collaborations [1]

Core Viewpoint - The company is focusing on internationalization as a long-term core development strategy, particularly targeting the EU market for product registration and market expansion [1] Group 1: Business Operations - Currently, the company's exports to the EU market primarily consist of raw materials, which represent a relatively small portion of the overall revenue [1] - Sales in the EU market are mainly conducted through a direct sales model with customers, supplemented by sales through distributors to ensure stable business progress [1] Group 2: Strategic Developments - The company has established a sales subsidiary in the Netherlands and is working on preparations for building a sales and registration system aimed at the EU market, in order to facilitate the future export of formulated products [1] - The company aims to continuously improve its global supply chain and sales layout to enhance its competitiveness in international markets [1]

Core Viewpoint - The company has entered into guarantee agreements to support its subsidiaries' financing needs, ensuring operational continuity and financial stability [3][5][13]. Group 1: Guarantee Agreements - In January 2026, the company’s subsidiary, Lijuz Pharmaceutical Group, signed guarantee agreements with three banks, with total guarantee amounts of RMB 10,000 million, RMB 30,000 million, and RMB 60,000 million [3]. - The guarantees are for Lijuz Pharmaceutical's wholly-owned or controlled subsidiaries, and there are no related party guarantees involved [3]. - The company has authorized its legal representative to sign relevant documents regarding the guarantees, assuming joint liability [4][5]. Group 2: Financing Support Framework - A framework agreement was established for Lijuz Group to provide continuous financing guarantees for its subsidiary, Lijuz Monoclonal Antibody, from January 1, 2025, to December 31, 2027, with an annual limit of RMB 21,000 million [5]. - The company will provide counter-guarantees based on its equity stake in Lijuz Monoclonal Antibody, ensuring financial backing until the end of Lijuz Group's guarantee obligations [5][15]. Group 3: Financial Health and Risk Management - As of January 31, 2026, the total guarantee balance of the company is RMB 228,478.14 million, which is 15.72% of the latest audited net assets [16]. - There are no overdue guarantees as of the same date, indicating effective risk management and financial health [17].

健康元药业集团 担保进展公告 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- | | 截至本公告日上市公司及其控股子公 | 228,478.14 | | 司对外担保余额（万元） | | | 对外担保余额占上市公司最近一期经 | 15.72 | | 审计净资产的比例（%） | | | 特别风险提示（如有请勾选） | □担保金额（含本次）超过上市公司最近一期经审 | | | 计净资产 50% | | | □对外担保总额（含本次）超过上市公司最近一期 | | | 经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达到或超 | | | 过最近一期经审计净资产 30% | | | 本次对资产负债率超过 70%的单位提供担保 | | 其他风险提示（如有） | 不适用 | 一、担保情况概述 证券代码：600380 证券简称：健康元 公告编号：临 2026-008 健康元药业集团股份有限公司 关于为控股子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 ...

Core Viewpoint - The company is advancing its TSLP monoclonal antibody for the treatment of moderate to severe COPD, with significant progress in clinical trials, positioning it as a leader in the domestic market for similar projects [1] Clinical Development - The Phase II clinical trials are progressing smoothly, and the Phase III clinical trial has completed CDE filing, with preparations underway [1] - The product targets the upstream TSLP pathway to block airway inflammation at its source, showing potential to reduce acute exacerbation rates in patients [1] Competitive Landscape - Currently, only AstraZeneca/Amgen's Tezepelumab has been commercialized, approved solely for asthma, while COPD indications are still in Phase III trials globally [1] - Other domestic companies are exploring similar indications, but the company's focus on COPD and its leading development progress provide a significant competitive edge [1] Market Strategy - The company has a well-established academic promotion system and commercialization channels in the respiratory field, enabling rapid market integration upon product launch [1] - Future plans include accelerating clinical progress, seizing research and registration opportunities, and exploring additional indications to maximize market potential [1]

Core Viewpoint - The company is leveraging AI technology to enhance its drug development process, aiming to improve both research efficiency and innovation capabilities across the entire value chain from drug discovery to commercialization [2] Group 1: AI Application in Drug Development - The company has completed the localization deployment of mainstream AI models, focusing on their application in innovative drug development in the core respiratory field [2] - During the molecular discovery phase, AI is utilized to analyze vast biomedical data, significantly increasing the probability of drug candidates' success by identifying potential cutting-edge targets in areas such as anti-inflammatory, bronchodilation, and respiratory infections [2] - In the clinical trial phase, AI optimizes trial design and enhances data analysis, which helps shorten project timelines and improve the scientific rigor of trial protocols [2] Group 2: Production and Commercialization - On the production side, AI is employed to simulate and optimize process parameters, ensuring cost control during large-scale production [2] - In the commercialization phase, the company uses AI to build a precise patient service system, having already identified health risks for nearly 100,000 chronic disease patients through AI models [2] - The company plans to continue deepening the practical application of AI in various stages of innovative drug development to enhance quality and efficiency [2]